Company Overview and News
E-commerce giant Alibaba Group Holding expects to achieve a record 1 billion orders in 24 hours during Singles’ Day on November 11, as the company pulls together its entire retail ecosystem in China and overseas to participate in the world’s largest online shopping festival this year.
IPhone and Tesla touchscreens once made her China’s richest woman. The U.S.-China trade war has made her the biggest loser in 2018 among Chinese billionaires. Zhou Qunfei, the chairman of consumer electronics supplier Lens Technology Co., has lost 66 percent of her fortune, or $6.6 billion, this year — the biggest drop in percentage terms among China’s wealthy — according to the Bloomberg Billionaires Index.
BABA 0700 AAPL
China is expected to be home to a 100 billion yuan (US$14 billion) market for intelligent connected vehicles by 2020, according to Industry and Information Technology Minister Miao Wei.
A Hong Kong artificial intelligence lab backed by e-commerce giant Alibaba Group Holding and SenseTime, the world’s most valuable AI start-up, has named seven companies that will receive funding under its accelerator programme.
BABA CKHUF 0700 CKHUY
(Oct 18): In China’s manufacturing heartland around the Pearl River Delta, Donald Trump’s 10 percent tariffs are causing little concern. The 25 percent duties that loom next year are another matter.
Fund managers in October turned the most pessimistic on global growth prospects since the depths of the financial crisis in the fall of 2008, but aren’t yet negative enough to offer a contrarian buy signal, according to Bank of America Merrill Lynch.
FB BABA GOOGL 0700 AAPL NFLX GOOG BIDU
Stocks listed in Hong Kong and China dropped on Monday, on worries the Trump Administration was stepping up its hardline approach to Beijing, which in turn sent markets lower across Asia.
CICHY MPNGY 0700 SNCHY CICHF AACAY CCB AACAF 0939
Chinese electric carmaker NIO Inc said on Monday it delivered 3,268 electric SUVs in the third quarter, exceeding its own target of 2,900-3,000 vehicles.
(Reuters) - Chinese electric carmaker NIO Inc (NIO.N) said on Monday it delivered 3,268 electric SUVs in the third quarter, exceeding its own target of 2,900-3,000 vehicles.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...